Last reviewed · How we verify
Ketamine plus magnesium group
Ketamine blocks NMDA receptors while magnesium enhances this antagonism and may provide neuroprotective and anti-inflammatory effects.
Ketamine blocks NMDA receptors while magnesium enhances this antagonism and may provide neuroprotective and anti-inflammatory effects. Used for Perioperative anesthesia and analgesia in cancer surgery patients.
At a glance
| Generic name | Ketamine plus magnesium group |
|---|---|
| Sponsor | National Cancer Institute, Egypt |
| Drug class | NMDA receptor antagonist combination |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ketamine is a non-competitive NMDA receptor antagonist that produces dissociative anesthesia and analgesia. Magnesium acts as a natural NMDA receptor channel blocker and may potentiate ketamine's effects while reducing excitotoxicity. The combination is being investigated for perioperative anesthesia and analgesia in cancer patients, potentially reducing pain and improving recovery outcomes.
Approved indications
- Perioperative anesthesia and analgesia in cancer surgery patients
Common side effects
- Dissociation
- Dizziness
- Nausea
- Emergence reactions
Key clinical trials
- Opioid Free and Opioid Based Anesthesia in Elective Lumbar Spine Surgery
- Magnesium Sulfate Versus Other Anesthesia Drugs to Reduce Agitation After Adenotonsillectomy in Pediatric Patients (NA)
- Ketamine Versus Magnesium Sulphate as Adjuvants for ESPB in Breast Cancer Surgery (PHASE2)
- Comparison of Nebulized Ketamine With Nebulized Magnesium Sulfate for the Prevention of Postoperative Sore Throat (NA)
- The Efface of Lidocaine vs. Magnesium Sulphate in the Management of Pain After Laparoscopic Cholecystectomy (PHASE1)
- The Efface of Ketamine vs. Magnesium Sulphate in the Management of Pain After Laparoscopic Cholecystectomy (PHASE1)
- Outcome of Multimodal Anesthesia Bern (NA)
- Esketamine Combined With Magnesium Sulfate for Postoperative Fatigue Syndrome in Patients Undergoing Laparoscopic Cholecystectomy (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketamine plus magnesium group CI brief — competitive landscape report
- Ketamine plus magnesium group updates RSS · CI watch RSS
- National Cancer Institute, Egypt portfolio CI